Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
5.62
-0.10 (-1.75%)
At close: Jun 20, 2025, 4:00 PM
5.64
+0.02 (0.36%)
After-hours: Jun 20, 2025, 4:00 PM EDT
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
$282,047
Profits / Employee
-$121,861
Market Cap
477.61M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
VALN News
- 12 days ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 16 days ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 18 days ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 26 days ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 5 weeks ago - Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States - GlobeNewsWire
- 6 weeks ago - Valneva SE (VALN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance - Seeking Alpha
- 6 weeks ago - Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly - GlobeNewsWire